15 Oct '21
15 Oct '21
“At present, the first in the class antithrombotic drug is being created,” said in the Organika company. “The fact that it affects a new molecular target, soluble guanylate cyclase, opens up new prospects for the prevention and treatment of thrombosis. Research is already beginning in the medical centers of Tomsk, Kemerovo, Novosibirsk, and further, in the final III phase, will be carried out in other cities of the country. ”Phase II works should be completed by the end of 2022 of the year. In parallel, preclinical studies are being conducted, revealing new directions for the use of this drug. One of them is the treatment and rehabilitation of patients with COVID-19, since the virus provokes thrombosis of the vessels of the lungs and other vital organs, which can lead to disability and death.
“This is a unique case when a domestic enterprise will carry out not only the final stage of developing a dosage form of an innovative drug patented by domestic developers, including abroad, but also synthesize a pharmaceutical substance from available raw materials, emphasized in the company. - The launch of the drug on the market is scheduled for 2025 ”.